Taysha Gene Therapies Asset Turnover 2020-2023 | TSHA
Taysha Gene Therapies asset turnover from 2020 to 2023. Asset turnover can be defined as the amount of sales or revenues generated per dollar of assets. The asset turnover ratio is an indicator of the efficiency with which a company is deploying its assets.
| Taysha Gene Therapies Asset Turnover Historical Data |
| Date |
|
|
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.481B |
$0.015B |
|
Taysha Gene Therapies Inc. is a patient-centric gene therapy company. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company's product pipeline includes TSHA-101, TSHA-118, TSHA-102, TSHA-103 and TSHA-104 which are in clinical stage. Taysha Gene Therapies Inc. is based in Dallas, Texas.
|
